Passage BIO, Inc. files 425

— Passage Bio, Inc. is acquiring Remix Therapeutics, Inc. in a merger transaction. Remix stockholders will receive shares of Passage Bio common stock. The headline deal value is based on an aggregate equity value of $226 million for Remix and an expected approximately $20 million for Passage Bio. (2) DEAL TERMS —